ADVERTISEMENT
ADVERTISEMENT
AI reshapes drug R&D, but limits remain
Panelists said the industry is still in the early stages of integrating AI into research and development.
-
1759953093.png)
Staff Reporter - Thu, 30, Apr 2026
- 16:29 EDT
- 7
Panelists for the AI in BioPharma R&D - Hype vs. Reality panel / USAIC
Boston, April 30: Artificial intelligence is accelerating drug development across the biopharma industry, cutting timelines and improving efficiency, but it has yet to transform how new medicines are discovered, top industry leaders from the pharma sector said Thursday.
At a panel on AI in biopharma research, executives and scientists said the technology is most useful today in improving speed, cost and execution. They said its role in generating new scientific ideas remains limited.
This post is for paying subscribers only
SUBSCRIBE NOW
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login